Inactive Instrument

Cardiome Pharma Corp. Share Price Nasdaq

CA14159U2020

Pharmaceuticals

End-of-day quote Nasdaq
- ^USD	-

27/05/20	Mark Corrigan Departs as CEO from Correvio Pharma Corp	CI
27/05/20	Justin Renz, CFO Departs from Correvio Pharma Corp	CI

Valuation: Cardiome Pharma Corp.

Market Cap	37.07M 32.32M 30.52M 27.71M 51.93M 3.56B 52.14M 366M 141M 1.81B 139M 136M 5.82B	P/E 2018	-7.1x	P/E 2019	-0.68x
Enterprise Value	70.97M 61.89M 58.44M 53.06M 99.42M 6.81B 99.84M 700M 270M 3.46B 267M 261M 11.14B	EV / Sales 2018	5.13x	EV / Sales 2019	1.87x
Free-Float	86.23%	Yield 2018 *	-	Yield 2019	-

* Estimated data More valuation ratios

Latest news: Cardiome Pharma Corp.

27/05/20	Mark Corrigan Departs as CEO from Correvio Pharma Corp	CI
27/05/20	Justin Renz, CFO Departs from Correvio Pharma Corp	CI
27/05/20	Correvio Pharma Corp. Announces Management Changes	CI
26/05/20	Mercury Pharma Group Limited completed the acquisition of Correvio Pharma Corp..	CI
15/05/20	Correvio Pharma Corp. - Shareholder/Analyst Call
04/05/20	Correvio Pharma Corp. Postpones Announcement of Financial Statements for the First Quarter Ended March 31, 2020	CI
30/03/20	Correvio Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2019	CI
29/03/20	Correvio Pharma Corp. Auditor Raises 'Going Concern' Doubt	CI
15/03/20	Mercury Pharma Group Limited entered into an arrangement agreement to acquire Correvio Pharma Corp. for $21.3 million.	CI
24/12/19	Correvio Pharma Corp. Receives Complete Response Letter from U.S. FDA for Brinavess and Provides Update on Recent Events	CI
11/12/19	Correvio Pharma to explore sale after FDA panel setback; shares hit record low	RE
10/12/19	Correvio Pharma Corp Announces Outcome of FDA Advisory Committee Meeting Review of Brinavess for the Treatment of Recent Onset Atrial Fibrillation	CI
18/11/19	Correvio Announces Presentation of New Brinavess™ Spectrum Data	CI

More news

Press Releases: Cardiome Pharma Corp.

21/05/20	Correvio Pharma : Obtains Final Order for Plan of Arrangement	PR
15/05/20	Correvio Pharma : Announces Results from Annual General and Special Meeting of Securityholders	PR
06/05/20	Correvio Pharma : Leading Independent Proxy Advisory Firm Glass Lewis Recommends That Correvio Shareholders Vote for the Arrangement With ADVANZ PHARMA	PR
04/05/20	Correvio Pharma : Announces Postponement of Its First Quarter 2020 Financial Results Due to Impacts From COVID-19	PR
01/05/20	Correvio Pharma : Leading Independent Proxy Advisory Firm ISS Recommends That Correvio Shareholders Vote for the Arrangement with ADVANZ PHARMA	PR

More press releases

Managers and Directors: Cardiome Pharma Corp.

Director	Title	Age	Since
Ram Ramkumar BRD	Director/Board Member	-	-
Andreas Stickler BRD	Director/Board Member	55	-
Robert Ford BRD	Director/Board Member	-	-

More insiders

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MERCK & CO., INC.	-0.19%	+2.04%	+80.19%	+36.80%	362B
MERCK KGAA	-1.22%	-1.22%	+19.95%	-17.53%	64.74B
HALOZYME THERAPEUTICS, INC.	+2.53%	+4.90%	+44.52%	+182.75%	12.76B
KYOWA KIRIN CO., LTD.	-0.29%	+2.94%	-4.00%	-16.51%	7.53B
SK BIOPHARMACEUTICALS CO., LTD.	-1.89%	-2.14%	-31.54%	-13.67%	4.38B
YUHAN CORPORATION	-2.06%	-4.41%	-36.00%	+2.04%	4.08B
BETTA PHARMACEUTICALS CO., LTD.	+1.48%	+3.64%	-29.60%	-14.61%	2.96B
SUPERNUS PHARMACEUTICALS, INC.	-2.14%	+0.86%	-8.77%	+47.68%	2.44B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.41%	+1.15%	-23.58%	-31.98%	1.93B
Average	-0.47%	+0.46%	+1.24%	+19.44%	51.46B
Weighted average by Cap.	-0.29%	+1.55%	+65.73%	+31.02%

See all sector performances

Correvio Pharma Corp is a Canada-based company, which is a specialty pharmaceutical company. The Company focused on providing acute services. It's portfolio brands includes: Xydalba (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio, (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm Aggrastat (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. Its products include Trevyent, a drug-device combination that is designed to deliver treprostinil, the treatment for pulmonary arterial hypertension.

Employees

Sector

Pharmaceuticals

More about the company

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

	2018	2019
Net sales	28.67M 25M 23.61M 21.44M 40.17M 2.75B 40.34M 283M 109M 1.4B 108M 105M 4.5B	32.63M 28.46M 26.87M 24.4M 45.72M 3.13B 45.91M 322M 124M 1.59B 123M 120M 5.12B
Net income	-16.58M -14.46M -13.65M -12.4M -23.22M -1.59B -23.32M -164M -63.1M -809M -62.28M -60.9M -2.6B	-35.18M -30.68M -28.97M -26.31M -49.29M -3.38B -49.49M -347M -134M -1.72B -132M -129M -5.52B
Net Debt	25.92M 22.6M 21.34M 19.38M 36.31M 2.49B 36.46M 256M 98.66M 1.26B 97.37M 95.21M 4.07B	33.9M 29.57M 27.92M 25.35M 47.5M 3.25B 47.69M 334M 129M 1.65B 127M 125M 5.32B

Cardiome Pharma Corp. Share Price Nasdaq

Stocks

CA14159U2020

Pharmaceuticals

Valuation: Cardiome Pharma Corp.

Latest news: Cardiome Pharma Corp.

Press Releases: Cardiome Pharma Corp.

Managers and Directors: Cardiome Pharma Corp.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile